Summary
Johnson & Johnson's 2011 Form 10-K highlights a diversified healthcare conglomerate with a strong global presence across its Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments. The company's decentralized management structure empowers its numerous operating companies worldwide. Despite facing intense competition and an increasingly stringent regulatory environment, Johnson & Johnson continues to invest significantly in research and development, demonstrating a commitment to innovation across its product lines. The report also touches upon operational aspects such as manufacturing facilities, raw material sourcing, and intellectual property, underscoring the company's robust infrastructure. While specific financial performance figures for 2011 are detailed in the incorporated financial statements, the narrative emphasizes the company's preparedness for future challenges through ongoing R&D and strategic market presence. Investors can infer a stable, albeit competitive, operating landscape for JNJ in 2011.
Financial Highlights
55 data points| Revenue | $67.22B |
| Cost of Revenue | $21.66B |
| Gross Profit | $45.57B |
| SG&A Expenses | $20.87B |
| Operating Income | $14.96B |
| Interest Expense | $532.00M |
| Net Income | $10.85B |
| EPS (Basic) | $3.94 |
| EPS (Diluted) | $3.86 |
| Shares Outstanding (Basic) | 2.75B |
| Shares Outstanding (Diluted) | 2.81B |
Key Highlights
- 1Johnson & Johnson operates through three primary segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics, offering a broad portfolio of health and well-being products.
- 2The company boasts a significant global footprint with over 250 operating companies in 60 countries, indicating substantial international market penetration.
- 3Significant investment in Research and Development (R&D) is a core strategy, with $7.5 billion spent in 2011, reflecting a commitment to innovation and product development.
- 4The company emphasizes its strong patent and trademark portfolio, crucial for protecting its innovations and maintaining competitive advantage, particularly for key products like REMICADE®.
- 5LEVAQUIN®, a significant product, lost market exclusivity in the U.S. in June 2011, leading to a substantial sales decline (54.1%) in 2011.
- 6The company acknowledges the rigorous and increasing regulatory environment impacting the drug, device, and diagnostics industries globally, which requires substantial compliance efforts and expense.
- 7Johnson & Johnson maintains effective disclosure controls and procedures and internal controls over financial reporting, as assessed by management and audited by independent auditors.